Venlafaxine-induced encephalopathy in term newborn

Research output: Contribution to journalArticlepeer-review


The use of venlafaxine, a selective serotonin and norepinephrine reuptake inhibitor, for the management of depression in women of childbearing age has been on the rise, and there have been multiple case reports in the literature tying venlafaxine in-utero exposure to a form of neonatal encephalopathy presenting as neonatal abstinence syndrome. We present the case of a 5-day-old term infant whose mother was on venlafaxine throughout her pregnancy and presented with hypothermia, poor feeding, and decreased activity level. She subsequently had a negative sepsis workup and required nasogastric tube feedings for 2 weeks with spontaneous recovery and no clinical sequelae post-discharge. This case highlights the non-trivial potential risk of venlafaxine withdrawal in exposed newborns and the need for close observation. We propose a management framework for such situations in affected infants.

Bibliographical note

Publisher Copyright:
© The Author(s) 2020.


  • encephalopathy
  • newborn
  • Venlafaxine

PubMed: MeSH publication types

  • Case Reports


Dive into the research topics of 'Venlafaxine-induced encephalopathy in term newborn'. Together they form a unique fingerprint.

Cite this